I spoke to him way back around when he was first hired. That’s it. He seemed like a way to allow Les to be more inside, because Dave remains outside, albeit with more info than true outsiders. <br /> <br /> I think your assessment of the situation is off. You are more bearish than Ex now. There is no possible way you can infer that the company wanting TLD essentially concurrent with publication is bad. They started this road on October 5, 2020. Do you honestly believe they’d release TLD bare naked without an explanation of the results. <br /> <br /> Maybe you don’t remember how AF works. A company touts its results when releasing TLD, AF gets two months or so until some conference to bash the “hype” and inaccurately frame the context of those results with his childish brain. <br /> <br /> NWBO can’t afford that route. These are new main endpoints that the FDA is turning to. The global definition of GBM has changed. Even if they hit all endpoints, they don’t have manufacturing certification in the UK yet. An early demand with no confirmed ability to produce would be terrible. Bare naked public TLD with nothing else would not speed an approval decision. <br /> <br /> That said, I hope we get news on manufacturing very soon, because then I believe the regulators will have everything they need to start a decision making process.